Updated:
Bellco Capital
Rebecka Belldegrun and Arie Belldegrun established Bellco Capital in 2003. Wealth originated from the 2017 Kite Pharma sale and prior biopharmaceutical exits.
Bellco Capital
Rebecka Belldegrun and Arie Belldegrun established Bellco Capital in 2003. Wealth originated from the 2017 Kite Pharma sale and prior biopharmaceutical exits. Rebecka serves as CEO while Arie holds board roles at portfolio companies. Allocations span life sciences, real estate, private equity and venture investments. Asset classes include direct co-investments, SPVs, private credit and property holdings. Confirmed positions link to Breakthrough Properties assets in San Diego, Boston, Philadelphia, Amsterdam and Oxford. Geographic reach covers North America and Europe. Strategy mixes buyout and growth approaches. The team includes Chief Investment Officer Josh Bradley. Additional offices remain limited to the Los Angeles headquarters. Adjacent vehicles encompass the California Institute for Immunology and Immunotherapy and board service at LACMA and Caltech. Rebecka Belldegrun holds trusteeships at Brentwood School and BabyFirstTV. No operational events from the last 24 months appear in available records. Bellco Capital operates through Breakthrough Properties, a joint venture with Tishman Speyer that controls lab and office campuses. Governance integrates family principals with external partners on shared boards. This hybrid model ties investment decisions to operating-company oversight in life sciences and real estate.
General information
Firm type
Single Family Office
Year founded
2003
Location
Region
North America
Country
United States
City
Los Angeles
Corporate office
Los Angeles, CA, United States
Principals
Rebecka Belldegrun
CEO
Arie Belldegrun
Co-founder
Josh Bradley
Chief Investment Officer
Dan Belldegrun
CEO of Breakthrough Properties
Ben Belldegrun
Co-Founder and Managing Partner of Aliment Capital
Sector focus
Frequently asked questions
Who runs investment decisions at Bellco Capital?
Rebecka Belldegrun serves as CEO. Josh Bradley holds the Chief Investment Officer role. Arie Belldegrun participates through board oversight at portfolio companies.
How is Bellco Capital related to Breakthrough Properties?
Bellco Capital co-owns Breakthrough Properties with Tishman Speyer. Rebecka Belldegrun, Arie Belldegrun and Dan Belldegrun sit on its board alongside Tishman Speyer executives.
Does Bellco Capital participate in fund commitments or only direct deals?
The office executes direct co-investments and SPVs. It also holds positions through private equity and private credit structures.
Where does the underlying wealth come from?
Wealth traces to the $11.9 billion sale of Kite Pharma and earlier biopharmaceutical ventures by Arie and Rebecka Belldegrun.
What investment stages does Bellco Capital typically target?
Activity centers on startup and growth stages in life sciences and technology.
Which sectors does Bellco Capital explicitly avoid?
No explicit avoidance list appears in available records.
How does Bellco Capital source proprietary deal flow?
Sourcing occurs through board networks at Allogene Therapeutics, Ginkgo Bioworks and university institutes including UCLA and the Weizmann Institute.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: